Literature DB >> 1377086

Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies.

D C Deecher1, M Teitler, D M Soderlund, W G Bornmann, M E Kuehne, S D Glick.   

Abstract

Assays using radioligands were used to assess the actions of ibogaine and harmaline on various receptor types. Ibogaine congeners showed affinity for opiate receptors whereas harmaline and harmine did not. The Ki for coronaridine was 2.0 microM at mu-opiate receptors. The Kis for coronaridine and tabernanthine at the delta-opiate receptors were 8.1 and 3.1 microM, respectively. Ibogaine, ibogamine, coronaridine and tabernanthine had Ki values of 2.08, 2.6, 4.3 and 0.15 microM, respectively, for kappa-opiate receptors. Long-lasting, dose-dependent behavioral effects of ibogaine have been reported. The possibility that these effects were due to irreversible binding properties of ibogaine at kappa-receptors was considered; however, radioligand wash experiments showed a rapid recovery of radioligand binding after one wash. A voltage-dependent sodium channel radioligand demonstrated Ki values in the microM range for all drugs tested. Using radioligand binding assays and/or 36Cl- uptake studies, no interaction of ibogaine or harmaline with the GABA receptor-ionophore was found. The kappa-activity of ibogaine (or an active metabolite) may be responsible for its putative anti-addictive properties whereas the tremorigenic properties of ibogaine and harmaline may be due to their effects on sodium channels.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1377086     DOI: 10.1016/0006-8993(92)90661-r

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  19 in total

1.  In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensis.

Authors:  Jan Carlo Delorenzi; Leonardo Freire-de-Lima; Cerli R Gattass; Deise de Andrade Costa; Liwen He; Martin E Kuehne; Elvira M B Saraiva
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

Review 2.  Herbal medicines for the management of opioid addiction: safe and effective alternatives to conventional pharmacotherapy?

Authors:  Jeanine Ward; Christopher Rosenbaum; Christina Hernon; Christopher R McCurdy; Edward W Boyer
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

3.  Neuropharmacological characterization of local ibogaine effects on dopamine release.

Authors:  M S Reid; K Hsu; K H Souza; P A Broderick; S P Berger
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine.

Authors:  J K Staley; Q Ouyang; J Pablo; W L Hearn; D D Flynn; R B Rothman; K C Rice; D C Mash
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

5.  Long-lasting ibogaine protection against NMDA-induced convulsions in mice.

Authors:  M B Leal; D O de Souza; E Elisabetsky
Journal:  Neurochem Res       Date:  2000-08       Impact factor: 3.996

6.  Pharmacological comparison of the effect of ibogaine and 18-methoxycoronaridine on isolated smooth muscle from the rat and guinea-pig.

Authors:  M K Mundey; N A Blaylock; R Mason; S D Glick; I M Maisonneuve; V G Wilson
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

7.  Ibogaine and the dopaminergic response to nicotine.

Authors:  I M Maisonneuve; G L Mann; C R Deibel; S D Glick
Journal:  Psychopharmacology (Berl)       Date:  1997-02       Impact factor: 4.530

8.  Effect of ibogaine on serotonergic and dopaminergic interactions in striatum from mice and rats.

Authors:  H Sershen; A Hashim; A Lajtha
Journal:  Neurochem Res       Date:  1994-11       Impact factor: 3.996

9.  The putative anti-addictive drug ibogaine is a competitive inhibitor of [3H]MK-801 binding to the NMDA receptor complex.

Authors:  P Popik; R T Layer; P Skolnick
Journal:  Psychopharmacology (Berl)       Date:  1994-05       Impact factor: 4.530

10.  Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity.

Authors:  P M Sweetnam; J Lancaster; A Snowman; J L Collins; S Perschke; C Bauer; J Ferkany
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.